Acorda/Biogen Idec's Ampyra becomes first US FDA-approved drug to improve walking in MS
25 January 2010
Katie McQue
The US FDA has approved
Acorda Therapeutics/
Biogen Idec's oral drug Ampyra (dalfampridine; formerly fampridine SR) to improve walking in patients with multiple sclerosis, making it the first drug to be approved for the management of specific symptoms of the disease.
New York-based Acorda's share...
Please Login to read the full article.
25 January 2010
Katie McQue
New York-based Acorda's share...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
